Revenue | Over $500 million See Exact Annual Revenue |
---|---|
Employees | N/AExact Company Size |
Primary Industry | 325411 Medicinal & Botanical Manufacturing |
Additional NAICS Codes | 325412 Pharmaceutical Preparation Manufacturing |
Address | 2275 Half Day Rd Ste 200 Deerfield, IL 60015 |
Novartis Gene Therapies | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
---|---|---|---|
2023 | Over $500 million Details in Premium Report | ||
2022 | |||
2021 | |||
2020 | |||
2019 |
1-Year Growth Rate: 3-Year Growth Rate (CAGR): |
Novartis Gene Therapies P&L | $ Millions |
---|---|
Revenue (Sales) | |
Cost of Goods Sold | |
Gross Profit | |
Operating Expenses | |
Advertising | |
Salaries and wages | |
Other Operating Expenses | |
Total Operating Expenses | |
Operating Income | |
EBITDA | |
EBIT (Earnings Before Interest and Taxes) | |
Net Profit | |
Trademark | Date |
---|---|
ONEGENE PROGRAM Providing information regarding insurance coverage and reimbursement for prescription drugs; financial administration of a patient assistance program for providing prescription drugs at reduced cost | 09/20/2019 |
ONREPLA Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparation in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression | 11/06/2017 |
GENREPLA Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparation in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression | 11/06/2017 |
Company | Headquarters | Revenue ($ MM) |
---|---|---|
XYMOGEN | Orlando, FL | 100 |
AVANTI NUTRITIONAL LABORATORIES | Miami Lakes, FL | 37 |
NUTRITION FORMULATORS | Miramar, FL | 36 |
RTPR | Cabot, AR | 33 |
INTEGRATED BOTANICS | Fort Worth, TX | 29 |
COSMAX NBT USA | Garland, TX | 29 |
CJB INDUSTRIES | Valdosta, GA | 28 |
ALTERNATIVE LABORATORIES | Naples, FL | 28 |
S&B PHARMA | Azusa, CA | 28 |
Company | Headquarters | Revenue ($ MM) |
---|---|---|
ABBOTT LABORATORIES | Abbott Park, IL | 100 |
ALLERGAN | North Chicago, IL | 67 |
ASTELLAS US | Northbrook, IL | 11 |
FRESENIUS KABI | Lake Zurich, IL | 11 |
HOSPIRA | Lake Forest, IL | 10 |
HORIZON THERAPEUTICS USA | Deerfield, IL | 5 |
Company | Revenue ($ MM) |
---|---|
|